tiprankstipranks
Trending News
More News >
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics (ALLO) Income Statement

Compare
1,567 Followers

Allogene Therapeutics Income Statement

Last quarter (Q3 2025), Allogene Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Allogene Therapeutics's net income was $-41.40M. See Allogene Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 22.00K$ 95.00K$ 156.00K$ 114.09M$ 0.00
Gross Profit
$ 22.00K$ 95.00K$ -14.14M$ 114.09M$ -11.54M
Operating Expenses
$ 273.22M$ 327.83M$ 321.40M$ 294.28M$ 246.70M
Depreciation and Amortization
$ 13.64M$ 14.20M$ 14.29M$ 10.45M$ 11.54M
EBITDA
$ -243.33M$ -313.07M$ -321.24M$ -169.74M$ -238.68M
Operating Income
$ -273.20M$ -327.74M$ -335.54M$ -180.19M$ -258.24M
Other Income/Expenses
$ 16.05M$ 472.00K$ -4.88M$ -1.86M$ 8.02M
Pretax Income
$ -257.15M$ -327.26M$ -340.41M$ -182.05M$ -250.22M
Net Income
$ -257.59M$ -327.26M$ -340.41M$ -182.05M$ -250.22M
Per Share Metrics
Basic EPS
$ -1.32$ -2.09$ -2.38$ -1.34$ -2.08
Diluted EPS
$ -1.32$ -2.09$ -2.38$ -1.34$ -2.08
Weighted Average Shares Outstanding
194.81M 156.93M 143.15M 135.82M 120.37M
Weighted Average Shares Outstanding (Diluted)
194.81M 156.93M 143.15M 135.82M 120.37M
Currency in USD

Allogene Therapeutics Earnings and Revenue History